Tesla could be a $10,000 stock in a decade, says longtime bull Ron Baron
Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences Corp (NYSE:EW), sold a total of 13,000 shares of common stock on November 10, 2025, for approximately $1,080,093. The transaction comes as Edwards Lifesciences trades near its 52-week high of $87.09, with the stock delivering a 26.95% return over the past year. InvestingPro data shows the company maintains a "GOOD" financial health rating.
The sales were executed in two transactions. The first involved 2,974 shares sold at an average price of $83.2999, with prices ranging from $83.270 to $83.415. The second transaction involved 10,026 shares, sold at an average price of $83.0201, with prices ranging from $82.270 to $83.260. Despite this insider sale, InvestingPro tips reveal management has been aggressively buying back shares, and the stock generally trades with low price volatility.
On the same day, Ullem also exercised options to acquire 13,000 shares of Edwards Lifesciences common stock at a price of $59.2567, for a total value of $770,337. These options stemmed from an Employee Stock Option (Right to Acquire). Edwards currently trades at a P/E ratio of 36.77, reflecting its premium valuation. For comprehensive analysis including 10 more ProTips and a detailed Pro Research Report, visit InvestingPro.
In other recent news, Edwards Lifesciences reported strong third-quarter financial results, exceeding Wall Street expectations. The company achieved an adjusted earnings per share of $0.67, surpassing the anticipated $0.59, and reported revenue of $1.55 billion, which exceeded the forecast of $1.5 billion. This performance was highlighted by a 12.6% organic top-line growth, driven by robust results across all business segments, including over 10% growth in its transcatheter aortic valve replacement (TAVR) business.
Following these results, Bernstein raised its price target for Edwards Lifesciences to $90, maintaining a Market Perform rating. Canaccord Genuity also increased its price target to $84, while keeping a Hold rating, noting the company’s quarterly sales exceeded both their estimate and consensus expectations. Additionally, Raymond James upgraded the company’s stock rating to Outperform, citing fewer reasons to remain neutral on the company. These developments reflect a positive sentiment from analysts regarding Edwards Lifesciences’ recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.